Opportunities and Challenges of Kava in Lung Cancer Prevention

Breanne Freeman, Jessica Mamallapalli, Tengfei Bian, Kayleigh Ballas, Allison Lynch, Alexander Scala, Zhiguang Huo, Kristianna M. Fredenburg, Adriaan W. Bruijnzeel, Carolyn J. Baglole, Junxuan Lu, Ramzi G. Salloum, John Malaty, Chengguo Xing

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Lung cancer is the leading cause of cancer-related deaths due to its high incidence, late diagnosis, and limited success in clinical treatment. Prevention therefore is critical to help improve lung cancer management. Although tobacco control and tobacco cessation are effective strategies for lung cancer prevention, the numbers of current and former smokers in the USA and globally are not expected to decrease significantly in the near future. Chemoprevention and interception are needed to help high-risk individuals reduce their lung cancer risk or delay lung cancer development. This article will review the epidemiological data, pre-clinical animal data, and limited clinical data that support the potential of kava in reducing human lung cancer risk via its holistic polypharmacological effects. To facilitate its future clinical translation, advanced knowledge is needed with respect to its mechanisms of action and the development of mechanism-based non-invasive biomarkers in addition to safety and efficacy in more clinically relevant animal models.

Original languageEnglish (US)
Article number9539
JournalInternational journal of molecular sciences
Volume24
Issue number11
DOIs
StatePublished - Jun 2023

All Science Journal Classification (ASJC) codes

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this